Meet with... NCATS
MassBio HQ , 300 Technology Square, 8th Floor , Cambridge , MA 02139
November 05, 2014 from 11:00 AM to 14:00 PM (EST)
$10 - $35
Translation is a team sport and NCATS wants to play
Meet with the newest institute at the NIH called The National Center for Advancing Translational Science (NCATS). By design, NCATS was formed to transform the translational science process so that new treatments and cures for disease can be delivered to patients faster.
NCATS directly addresses the obstacles scientists face when developing a novel drug, device or other intervention. They are committed to uncovering new technologies and other approaches that could greatly accelerate the development and deployment of solutions that all translational researchers can use.
The NCATS approach is distinct in many ways and has already made a significant impact. Successes include 19 INDs that have been cleared by the FDA, twelve projects have been evaluated in clinical trials, and three agents have gone as far as Phase II human clinical trials. Additionally, third-party investors have licensed seven agents that have been developed through NCATS programs.
Join us to learn more about NCATS and their innovative approach. Following an overview of NCATS' opportunities and key areas of interest, don't miss the opportunity to introduce yourself during the networking lunch. Finally, for those companies who applied online and were approved, one-on-one meetings with NCATS will provide a forum to further discuss your company.
NCATS is seeking to collaborate with companies focusing on translating bench top discoveries to clinical hypothesis testing.
10:00 AM | Registration & Networking
10:30 AM | Presentation & Q&A
12:00 PM | Lunch & Networking
1:00 PM | One-on-one Meetings*
4:30 PM | Program Close
*Companies must apply ahead of time and be approved for a one-on-one meeting. The application period has closed on October 15.
NIH NCATS Participating Representative:
Nora Yang | Director of Portfolio Management and Strategic Operations , National Center for Advancing Translational Sciences, National Institutes of Health read bio»
About the National Center for Advancing Translational Sciences :
The National Center for Advancing Translational Sciences (NCATS) is the newest of 27 Institutes and Centers (ICs) at the National Institutes of Health (NIH). This Center was established in December 2011 to transform the translational science process so that new treatments and cures for disease can be delivered to patients faster. The mission of the National Center for Advancing Translational Sciences (NCATS) at the National Institutes of Health (NIH) is to catalyze the generation of innovative methods and technologies that will enhance the development, testing and implementation of diagnostics and therapeutics across a wide range of human diseases and conditions. Read more about NCATS»
Presentation & Lunch
$25 | General Public
$35 | General Public Onsite
Includes presentation, Q&A, and lunch. All attendees must pay this fee, regardless of one-on-one meeting status. Registration to attend the presentation, Q&A, and lunch will remain open until November 4 (or full).
FREE | Application
FREE | Accepted Companies
Companies must have applied for a one-on-one meeting ahead of time. The one-on-one application period has closed on Wednesday, October 15, 2014. Your application will be reviewed and you will be notified of acceptance on Wednesday, October 29, 2014. Acceptance of a one-on-one meeting is not guaranteed as all applications must be approved.
300 Technology Square, 8th Floor
Cambridge, MA 02139
NIH NCATS Representative's Biography:
Nora Yang | Director of Portfolio Management and Strategic Operations , National Center for Advancing Translational Sciences, National Institutes of Health
Nora Yang is the Director of Portfolio Management and Strategic Operations at the National Center for Advancing Translational Sciences (NCATS), NIH. In her current role, Nora Yang is responsible for planning, identifying and managing collaboration opportunities and partnerships, developing new business models to improve efficiency and effectiveness of translational sciences, building portfolio and project management capabilities, and implementing best practices of managing public and private partnerships for the NIH National Center for Advancing Translational Sciences (NCATS). She took a leadership role in building and managing the rare and neglected disease drug development portfolio within NCATS, which has taken 4 investigational drugs into rare disease patients in 7 clinical trials within 3 years. Within 4 years, 3 assets within the portfolio have been acquired by pharma partners with a collective deal value of US$1.12 billion. Prior to joining NCATS at NIH, Dr. Yang led global product development teams to manage and develop novel therapeutics for metabolic diseases and oncology indications at Eli Lilly & Co. and Amgen, Inc. She also worked with startup companies and VC firms to build and evaluate business plans and raise series A funding for startup companies. Nora holds a Ph.D. in chemistry from the Salk Institute of biological Research and the University of California, San Diego, and a Master’s degree in business management from Stanford University, Graduate School of Business.
About the Meet with... Series:
The purpose of the Meet with Series events sponsored by J-Labs is to help start-up entrepreneurs, as well as the academic community, connect with potential partners, such as big pharma or other investment corporations, through one-on-one meetings. It is also a chance for the featured corporation to outline their specific business development goals and clarify what types of products or research they are interested in and how best to approach them to get the partnering process started. Past participants include the Wellcome Trust, MedImmune Ventures, NCI, Mercury Fund, Correlation Ventures, Breakout Labs, New Enterprise Associates, and Thomas McNerney & Partners.